amikacin has been researched along with Infections, Serratia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bosman, N; Chibabhai, V; Lowman, W; Nana, T; Thomas, T | 1 |
| Hashemian, MN; Khodabande, A; Rahimi, F | 1 |
| Bégué, T; Bouchaud, O; Jauréguy, F; Lefort, A; Lortholary, O; Righi, S; Robineau, M | 1 |
| Cheng, KC; Chuang, YC; Huang, GC; Wu, LT; Yu, WL | 1 |
| Diniz, EM; Fontes, RB; Hirooka, TM; Matushita, H; Pinto, FC | 1 |
| Baron, D; Bugnon, D; Caillon, J; Drugeon, H; Kergueris, MF; Le Conte, P; Potel, G; Xiong, YQ | 1 |
2 review(s) available for amikacin and Infections, Serratia
| Article | Year |
|---|---|
Were all carbapenemases created equal? Treatment of NDM-producing extensively drug-resistant Enterobacteriaceae: a case report and literature review.
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Child; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Meropenem; Serratia Infections; Serratia marcescens; Thienamycins; Treatment Outcome | 2018 |
Cerebral abscess caused by Serratia marcescens in a premature neonate.
Topics: Amikacin; Anti-Bacterial Agents; Brain Abscess; Diseases in Twins; Humans; Infant, Newborn; Male; Meropenem; Serratia Infections; Serratia marcescens; Thienamycins | 2007 |
4 other study(ies) available for amikacin and Infections, Serratia
| Article | Year |
|---|---|
Serratia marcescens keratitis after photorefractive keratectomy.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Ceftazidime; Contact Lenses, Hydrophilic; Corneal Ulcer; Drug Therapy, Combination; Equipment Contamination; Eye Infections, Bacterial; Female; Humans; Myopia; Photorefractive Keratectomy; Postoperative Complications; Serratia Infections; Serratia marcescens | 2009 |
Serratia marcescens prosthesis infection successfully treated with meropenem after imipenem failure.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Arthroplasty, Replacement, Knee; Drug Resistance, Bacterial; Female; Humans; Imipenem; Knee Prosthesis; Meropenem; Prosthesis-Related Infections; Serratia Infections; Serratia marcescens; Thienamycins; Treatment Failure; Treatment Outcome | 2005 |
Clinical experiences of the infections caused by extended-spectrum beta-lactamase-producing Serratia marcescens at a medical center in Taiwan.
Topics: Amikacin; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Polymerase Chain Reaction; Serratia Infections; Serratia marcescens; Taiwan | 2006 |
In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Drug Administration Schedule; Endocarditis, Bacterial; Female; Infusions, Intravenous; Models, Biological; Rabbits; Serratia Infections; Serratia marcescens | 1996 |